HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Lupin Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 96 filings·Updated 9 Oct 2026
Showing 10 of 96 filings.
9 Oct 20261 filing
Company UpdateCertificate under SEBI (Depositories and Participants) Regulations, 2018

Lupin Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 12:18View Source
28 Sept 20262 filings
Insider Trading / SASTClosure of Trading Window

Lupin Limited: Trading Window Closure from October 01, 2026 till 48 hours after the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026

Lupin Limited: Trading Window Closure from October 01, 2026 till 48 hours after the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026

Filed 15:42View Source
Company UpdatePress Release / Media Release

Lupin Receives US FDA Tentative Approval for Apixaban Oral Suspension (1.25 mg/mL) via 505(b)(2)

Regulatory milestone

  • Lupin receives tentative FDA approval for Apixaban Oral Suspension 1.25 mg/mL via 505(b)(2).

Manufacturing readiness

  • Final approval would enable manufacturing at Somerset, New Jersey facility for U.S. supply.

Product scope

  • Oral liquid apixaban formulation for adults, including those who have difficulty swallowing tablets.
Filed 09:11View Source
21 Sept 20262 filings
Company UpdateESOP/ESOS/ESPS

Lupin Allots 24,111 ESOP Shares; Capital Increases

Capital / Securities

  • Allotted 24,111 fully paid-up equity shares of ₹2 on vested ESOP options.
  • Issued and paid-up capital now ₹91,45,79,944 comprising 45,72,89,972 shares.
Filed 16:25View Source
Company UpdateAllotment of ESOP / ESPS

Intimation of allotment of 24,111 equity shares under ESOP.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 16:14View Source
8 Sept 20261 filing
Company UpdateAnalyst / Investor Meet

Lupin to participate in Kotak Healthcare and J.P. Morgan India investor meetings in September 2026

Meeting Details

  • Sept 17, 2026 — Kotak Healthcare Conference; in-person group meet.
  • Sept 21, 2026 — J.P. Morgan India Conference; in-person group meet.

Additional Notes

  • Presentations, if any, will align with Lupin’s published materials.
Filed 16:38View Source
28 Aug 20261 filing
Company UpdateGeneral

Lupin receives independent Crisil ESG ratings for FY26, placing the company in the 'Strong' category.

ESG rating update

  • Crisil ESG Ratings assigned ESG 69 and Core ESG 65 for FY26, placing Lupin in 'Strong' category.
  • Rating prepared independently using publicly available information; Lupin did not engage Crisil ESG Ratings.
Filed 09:41View Source
25 Aug 20262 filings
Company UpdateAllotment of ESOP / ESPS

Intimation of allotment of 30967 equity shares under ESOP.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 17:35View Source
Company UpdateESOP/ESOS/ESPS

Lupin Allots ESOP Shares; Capital Increases

Share Capital Update

  • Allotted 30,967 fully paid-up shares under ESOP upon vested option exercise.
  • Issued and paid-up capital increased to ₹91,45,31,722 with 45,72,65,861 shares.
Filed 17:30View Source
24 Aug 20261 filing
Company UpdateGeneral

Lupin receives independent ESG rating of 60 (Adequate) based on public data

ESG Rating Disclosure

  • ESG rating of 60 assigned to Lupin, category Adequate, by ESG Risk Assessments & Insights Limited.
  • Lupin did not engage the firm; rating prepared from Lupin's public-domain data.
  • Disclosure for information and dissemination.
Filed 18:53View Source
Showing 10 of 96 filings